Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Receivables (2023 - 2026)

Cannabis Bioscience International Holdings' Receivables history spans 4 years, with the latest figure at $1266.0 for Q1 2026.

  • On a quarterly basis, Receivables fell 52.05% to $1266.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $1266.0, a 52.05% decrease, with the full-year FY2025 number at $15535.0, down 22.86% from a year prior.
  • Receivables hit $1266.0 in Q1 2026 for Cannabis Bioscience International Holdings, down from $21811.0 in the prior quarter.
  • Over the last five years, Receivables for CBIH hit a ceiling of $21811.0 in Q4 2025 and a floor of $1266.0 in Q1 2026.
  • Historically, Receivables has averaged $14263.8 across 4 years, with a median of $17041.0 in 2024.
  • Biggest five-year swings in Receivables: skyrocketed 102.38% in 2024 and later crashed 84.51% in 2025.
  • Tracing CBIH's Receivables over 4 years: stood at $19403.0 in 2023, then fell by 28.78% to $13819.0 in 2024, then skyrocketed by 57.83% to $21811.0 in 2025, then plummeted by 94.2% to $1266.0 in 2026.
  • Business Quant data shows Receivables for CBIH at $1266.0 in Q1 2026, $21811.0 in Q4 2025, and $18121.0 in Q3 2025.